Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

AbCellera gains as experimental drug reduces hot flashes in mid-stage trial

BUZZ-AbCellera gains as experimental drug reduces hot flashes in mid-stage trial

** Shares of AbCellera ABCL.O rise 32.2% to $9.08 premarket

** Co says a mid-stage trial showed its experimental drug significantly reduces the frequency and severity of moderate-to-severe hot flashes at four weeks versus placebo after a single dose

** ABCL635 is being developed as a non-hormonal, long-acting, subcutaneous treatment for moderate-to-severe vasomotor symptoms, commonly known as hot flashes, due to menopause

** Up to last close, stock up 102% YTD


(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

Recent news on AbCellera Biologics

See all news